Clinical Trial Update: Lenvatinib, Pembrolizumab, and Tumor Treating Fields (TTFields) for Second-line Treatment of Glioblastoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating lenvatinib, pembrolizumab, and Tumor Treating Fields for second-line glioblastoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• LENVIMA (lenvatinib)
• OPTUNE

Snippet

Sponsor: Tel Aviv Medical Center | Conditions: GBM | Phase 1, Phase 2 | Status: WITHDRAWN